Esperion is developing innovative therapies to prevent, treat, and reverse cardiovascular and metabolic diseases. We intend to commercialize innovative treatments that enhance the body's ability to regulate lipid and carbohydrate metabolism and reduce inflammation. We will continue to build our drug portfolio by leveraging our drug discovery and development experience and acquiring new compounds and technologies to translate scientific research into new Pathways to Better Health.

Esperion Development Pipeline

ETC-1002

Esperion's most advanced product candidate, ETC-1002 - a novel, once-daily, oral drug - is in Phase II clinical trials for patients who have, or are at risk for developing, cardiovascular and metabolic diseases. ETC-1002 is a small molecule metabolic regulator of imbalances in lipid and carbohydrate metabolism and inflammation, unique in its ability to equally inhibit both fatty acid and cholesterol synthesis as well as enhance fatty acid oxidation. Unlike current therapies that primarily target an individual risk factor, ETC-1002 regulates abnormal lipid and carbohydrate metabolism to improve multiple risk factors, thus having the potential to address the underlying causes of metabolic diseases.

Clinical trials information: http://clinicaltrials.gov/ct2/results?term=esperion

Second Generation Compounds

Esperion's second generation compounds are complementary to ETC-1002 and are protected by separate intellectual property estates. These small molecule compounds offer the opportunity to impact lipid and carbohydrate metabolism and inflammation. We intend to identify a novel lead compound in this category by year-end 2011.

HDL Mimetics

HDL mimetic therapies are designed to rapidly eliminate cholesterol and other lipids from the arterial wall and related tissues. Esperion is a recognized innovator in HDL mimetic therapy, having successfully developed the current standard in this field with recombinant apolipoprotein(apo)A-I Milano. ApoA-I is a protein that is the primary component of HDL. Esperion is taking advantage of their previous experience and leveraging recent advances in recombinant protein production to develop novel HDL therapies.

Esperion's HDL mimetics program is being optimized to efficiently formulate, develop and test therapies to identify a proprietary oxidation-resistant apoA-I. We are collaborating with the Cleveland Clinic to rapidly advance this novel technology. The combination of the Cleveland Clinic's scientific expertise with Esperion's experience in HDL therapy and existing drug-development infrastructure, position us to meet the unmet need in cardiovascular diseases.